JP2016510767A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510767A5
JP2016510767A5 JP2015561822A JP2015561822A JP2016510767A5 JP 2016510767 A5 JP2016510767 A5 JP 2016510767A5 JP 2015561822 A JP2015561822 A JP 2015561822A JP 2015561822 A JP2015561822 A JP 2015561822A JP 2016510767 A5 JP2016510767 A5 JP 2016510767A5
Authority
JP
Japan
Prior art keywords
crystal form
substantially similar
crystalline form
disease
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015561822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510767A (ja
Filing date
Publication date
Priority claimed from AU2013204159A external-priority patent/AU2013204159B2/en
Application filed filed Critical
Publication of JP2016510767A publication Critical patent/JP2016510767A/ja
Publication of JP2016510767A5 publication Critical patent/JP2016510767A5/ja
Pending legal-status Critical Current

Links

JP2015561822A 2013-03-15 2013-05-14 抗不安化合物の結晶形態 Pending JP2016510767A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361787436P 2013-03-15 2013-03-15
US61/787,436 2013-03-15
AU2013204159 2013-04-12
AU2013204159A AU2013204159B2 (en) 2013-03-15 2013-04-12 A Crystalline Form of an Anxiolytic Compound
PCT/AU2013/000497 WO2014138772A1 (en) 2013-03-15 2013-05-14 A crystalline form of an anxiolytic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018526A Division JP2018109011A (ja) 2013-03-15 2018-02-05 抗不安化合物の結晶形態

Publications (2)

Publication Number Publication Date
JP2016510767A JP2016510767A (ja) 2016-04-11
JP2016510767A5 true JP2016510767A5 (enExample) 2016-07-07

Family

ID=51628585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015561822A Pending JP2016510767A (ja) 2013-03-15 2013-05-14 抗不安化合物の結晶形態
JP2018018526A Pending JP2018109011A (ja) 2013-03-15 2018-02-05 抗不安化合物の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018018526A Pending JP2018109011A (ja) 2013-03-15 2018-02-05 抗不安化合物の結晶形態

Country Status (9)

Country Link
US (2) US9758516B2 (enExample)
EP (1) EP2970290B1 (enExample)
JP (2) JP2016510767A (enExample)
CN (2) CN105377850A (enExample)
AU (2) AU2013204159B2 (enExample)
CA (1) CA2905573C (enExample)
MX (1) MX369451B (enExample)
NZ (1) NZ712341A (enExample)
WO (1) WO2014138772A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492440A (zh) * 2013-03-15 2016-04-13 生态学有限公司 抗焦虑化合物的盐、共晶体和多晶型物
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2022003347A (es) * 2019-09-23 2022-04-11 Bionomics Ltd Formulaciones terapeuticas y usos de las mismas.
AU2023201463A1 (en) * 2023-03-08 2024-09-26 Bionomics Limited Method of treating social anxiety disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US20060004102A1 (en) * 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
WO2008046135A1 (en) * 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
AU2012253237B2 (en) * 2011-05-12 2015-09-24 Bionomics Limited Methods for preparing naphthyridines

Similar Documents

Publication Publication Date Title
JP2016510767A5 (enExample)
JP2021530565A5 (enExample)
JP2007532560A5 (enExample)
JP2018024682A5 (enExample)
JP2013049690A5 (enExample)
RU2015143643A (ru) Соль омекамтива мекарбила и способ ее получения
JP2013237682A5 (enExample)
JP2011522827A5 (enExample)
JP2014522388A5 (enExample)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
ES2613716T3 (es) Formas cristalinas de un derivado de purina
JP2014169319A5 (enExample)
JP2018516883A5 (enExample)
JP2010514806A5 (enExample)
JP2013538849A5 (enExample)
JP2015516425A5 (enExample)
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
JP2013503134A5 (enExample)
JP2020536893A5 (enExample)
JP2014530818A5 (enExample)
JP2012500819A5 (enExample)
JP2020502224A5 (enExample)
JP2016537326A5 (enExample)
JP2010514725A5 (enExample)
JP2015506987A5 (enExample)